|1.||Diamant, Michaela: 14 articles (10/2015 - 10/2006)|
|2.||Han, Jenny: 14 articles (07/2014 - 09/2004)|
|3.||Hoogwerf, Byron J: 12 articles (08/2013 - 05/2006)|
|4.||Parkes, David G: 11 articles (04/2014 - 02/2004)|
|5.||Buse, John B: 10 articles (07/2014 - 11/2004)|
|6.||Trautmann, Michael: 10 articles (04/2012 - 11/2005)|
|7.||Taylor, Kristin: 10 articles (05/2011 - 09/2004)|
|8.||Nielsen, Loretta L: 10 articles (03/2009 - 02/2004)|
|9.||Best, Jennie H: 9 articles (01/2015 - 01/2011)|
|10.||Rosenstock, Julio: 9 articles (05/2014 - 05/2005)|
|1.||Weight Loss (Weight Reduction)
03/01/2009 - "In clinical trials, exenatide QW significantly improved glycemic control, resulted in patient weight loss, and was well tolerated in patients with T2DM. "
01/01/2013 - "Clinical use of Exenatide is associated with significant improvement in glycemic control and major weight loss (8.3±4.3 kg at 1 year) in obese subjects with type 2 diabetes. "
05/01/2008 - "An 82-week, open-label extension trial has shown that exenatide is well tolerated and that the benefits, including improved glycemic control, weight loss, and mitigation of cardiovascular risk factors, are sustained."
03/01/2015 - "Long-term once weekly exenatide treatment was generally well tolerated with sustained glycemic improvement, weight reduction, and improved markers of cardiovascular risk in patients with type 2 diabetes. "
01/01/2013 - "Overall, both cohorts achieved improved glycemic control, which was accompanied by a mean weight loss in the exenatide BID cohort."
|2.||Body Weight (Weight, Body)
06/01/2014 - "Presented here is a case of a morbidly obese patient with type 2 diabetes using exenatide who dramatically lost her body weight in a year and experienced improved glycemic control. "
10/01/2012 - "These results suggest that a 6-month exenatide injection therapy significantly improved patients' HbA1c levels and body weights without causing serious adverse effects in Korean patients with type 2 diabetes."
07/01/2012 - "In this pooled analysis, exenatide BID improved glycemic control and body weight, and had generally beneficial effects on blood pressure and lipid levels in patients regardless of baseline age, sex, race, duration of diabetes, or BMI. "
01/01/2007 - "At week 30, exenatide was associated with a significant reduction in mean (SD) body weight from baseline (-2.1 [0.2] kg), with progressive reductions after 2 years (-4.7 [0.3] kg; P < 0.001 vs baseline). "
04/03/2007 - "Exenatide therapy improved glycemic control, reduced body weight, and caused gastrointestinal symptoms more than placebo in patients with type 2 diabetes that was suboptimally controlled with TZD therapy. "
|3.||Type 2 Diabetes Mellitus (MODY)
03/01/2013 - "Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 led, in 66.8% of the population, to a statistically significant reduction in HbA(1c) levels in the first three-six months of the treatment; after 12 months of treatment, 25% of the population was still showing an improvement in HbA(1c) of > 2.0%. "
04/01/2013 - "Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 over a period of 24 months has led to an improvement in HbA1c level by 1.51%, and BMI level was reduced by 2.37 after two years of Byetta treatment."
03/01/2013 - "Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus."
06/01/2012 - "Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus."
05/01/2013 - "Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials."
|4.||Hypoglycemia (Reactive Hypoglycemia)
03/01/2010 - "Clinical studies demonstrate that combined administration of sulfonylureas with exenatide can induce hypoglycemia in type 2 diabetic subjects. "
01/01/2015 - "The safety and tolerability profile of exenatide QW compared with non-GLP-1RA comparators was similar overall, with the exception of a lower incidence of hypoglycemia and anticipated differences in gastrointestinal and injection site-related adverse events."
11/01/2014 - "Symptomatic hypoglycemia was more common in the group on exenatide, but this occurred in only 5 patients, and the clinical significance of this is uncertain. "
08/01/2014 - "At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide; no dulaglutide-treated patients reported severe hypoglycemia. "
07/01/2014 - "Incidence of hypoglycemia was numerically lower with exenatide BID in all tertiles. "
08/01/2010 - "This study shows that exendin-4 therapy improves cognitive function and ameliorates impaired hippocampal synaptic plasticity in dietary-induced obesity."
11/01/2015 - "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study."
01/01/2015 - "This study aimed to investigate the benefits of exendin-4 treatment on brown adipose tissue (BAT) in C57BL/6J mice with high-fat diet (HFD)-induced obesity. "
08/01/2013 - "In addition, recent studies have been published on the use of exenatide in the management of pediatric obesity and newly diagnosed type 1 diabetes. "
02/01/2012 - "These preliminary data suggest that exenatide should be evaluated in larger, well-controlled trials for its ability to reduce BMI and improve cardiometabolic risk factors in youth with extreme obesity."
|2.||Glucagon-Like Peptide 1 (GLP 1)
|6.||glucagon-like peptide receptor (receptor, glucagon-like peptide)
|8.||glargine (insulin glargine)
|2.||Gastric Bypass (Roux-en-Y Gastric Bypass)
|4.||Transplantation (Transplant Recipients)